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Abstract
Background: Ultrasound contrast agents (UCAs) allow the enhancement of vascular definition,
thereby providing more diagnostic information. LK565 is a new second-generation UCA based on
synthetic polymers of aspartic acid which is eliminated from the blood stream via phagocytosis.
LK565 forms very stable air-filled microspheres and is capable of repeated passage through the
pulmonary capillary bed after peripheral intravenous injection. This characteristic allows
examination of the cardiac function or extracardiac vessel abnormalities up to 15 minutes.
Methods: A phase one clinical study was conducted on 15 healthy volunteers to identify the
development of an undesirable immune response. Phagocytosis capacity, TNF-α secretion, and
MHC class II upregulation of monocytes was monitored, as well as microsphere specific antibody
development (IgM, IgG). Furthermore, the kinetics of the activation surface markers CD69, CD25,
CD71, and CD11b on leukocytes were analyzed.
Results: Due to LK565-metabolism the administration of the UCA led to saturation of phagocytes
which was reversible after 24 hrs. Compared to positive controls neither significant TNF-α
elevation, neither MHC class II and activation surface markers upregulation, nor specific antibody
development was detectable.
Conclusion: The administration of LK565 provides a comfortable duration of signal enhancement,
esp. in echocardiography, without causing a major activation cascade or triggering an adaptive
immune response. To minimize the risk of undesirable adverse events such as anaphylactoid
reactions, immunological studies should be included in clinical trials for new UCAs. The use of
LK565 as another new ultrasound contrast agent should be encouraged as a safe means to provide
additional diagnostic information.
Background
Echocardiography allows the analysis of ventricular
motion and heart-valve morphology. The discovery that
injection of small air bubbles dispensed in saline are
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capable of causing an opacification of the heart [1,2]
started an enormous effort to develop contrast agents to
assist in diagnosing coronary artery disease and myocar-
dial infarction [3]. Early developments led to stabilized
bubbles in hyperosmolar solutions [4]. Albumin-stabi-
lized bubbles were one of the first contrast agents to allow
examination of both ventricles [5], but there are stability
problems in patients with elevated pulmonary pressure
[6]. Second-generation contrast agents improved the con-
trast especially in patients with subnormal echo signals
[7-9]. LK565 and comparable substances represent a new
concept in contrast agents as it consists of small, stable,
air-filled particles [10] that provides a good contrast in
both ventricles (figure 1, 2). Due to its high stability,
LK565 improves examination of cardiac morphology and
function as well as extracardiac vessel abnormalities for at
least 15 minutes [11] (figure 3).
The particles consist of a synthetic polymer of aspartic
acid. Via peptide bonds, the molecules form bold, stable
beads filled with air. The average size of LK565 particles is
3 µm in diameter (figure 1). Because of their size and even
polymeric surface the beads have similarities to microor-
ganisms. This circumstance implies the induction of an
immune response, which needs to be considered.
Results from previous studies indicate that phagocytes are
responsible for eliminating the contrast agent from the
blood stream [11]. In vitro, it has been shown that macro-
phages and neutrophils quickly devour the LK565 parti-
cles. Preliminary studies proved that the LK565 particles
are phagocytosed by macrophages, resulting in slight acti-
vation with an increase in the intracellular calcium con-
tent. However, there were no symptoms of a respiratory
burst [12].
The activation of macrophages can lead to different condi-
tions: no activation, normal activation, and overreaction.
In the last case, over-expression of tumor necrosis factor
alpha (TNF-α) can lead to a septic shock by induction of
intravascular blood clots apart from other effects, which
may result in disseminated intravascular coagulation
[13,14]. Furthermore, macrophages act as antigen-pre-
senting cells which are highly important to induce an
adaptive immune response, i.e. specific antibody produc-
tion. It is probable that the LK565 particles attract antigen-
presenting cells to present LK565 fragments as antigens.
This may induce the production of specific antibodies
against the contrast agent, which in rare cases could result
in pathogenic immune reactions. The aim of this study
was to examine a possible immune response to LK565
considering phagocytosis, TNF-α secretion by macro-




The experiment was approved by the local ethics commit-
tee (registration number 708/98). After medical examina-
tion, 15 healthy male volunteers under the age of 30 were
enrolled in this phase one clinical study. Each volunteer
was exposed to a single dose of the contrast agent LK565
applied intravenously. Four participants were exposed to
the contrast agent LK565 for the second time because they
had already been involved in a prior study [11]. The 15
volunteers were divided up into 3 groups (n = 5). The first
group received 0.15 mg/kg bodyweight, the second group
0.4 mg/kg bodyweight and finally the third group 0.7 mg/
kg LK565.
Contrast agent
Prior to application, the contrast agent LK565 was dis-
solved in 10 ml physiological sodium chloride solution
(37°C) under sterile conditions. To eliminate aggrega-
tions, the solution was filtered using a 20 µm mesh just
before intravenous injection.
Sampling
Heparinized blood samples (2 ml) were taken before
application (t = 0), after 2 h, 6 h, 24 h, 48 h, 72 h, 96 h,
and 1 ml after 10 d, 12 d and 14 d. For routine analysis,
additional blood samples were drawn before and 2 hours
after intravenous contrast agent injection. The volunteers
were under medical care throughout the whole
experiment.
Phagocytosis
Phagocytosis capacity was determined in vitro before (t =
0) and after 2 h, 6 h and 24 h with Phagotest™ (Becton
Electron micrograph of LK565 Figure 1
Electron micrograph of LK565 Electron micrograph of 
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Dickinson, Germany) and analyzed via flow cytometry
(FACScalibur™, BectonDickinson, Germany). FITC-
labeled E. coli, which were opsonized with antibodies and
complement factors, were incubated with leukocytes.
After incubation, the increased fluorescence of the phago-
cytes was due to the uptake of bacteria. The fluorescence
intensity is dependent on the amount of phagocytosed
bacteria. A sample chilled on ice was used for control.
Tumor necrosis factor alpha (TNF-α)
Intracellular TNF-α production in monocytes and macro-
phages was analyzed before (t = 0) and after 2 h, 6 h, and
24 h. For detection, an anti-human TNF-α Pycoerythrin
(PE) monoclonal antibody (mAb) was applied
(Pharmingen, Germany). The specificity of the antibody
had been validated in blocking experiments. To 40 µl
blood, 145 µl RPMI and 15 µl 40 µM Monensin were
added (Monensin prevents cytokine release by blocking
the golgi apparatus). Cells were incubated for 2 h at T =
37°C and 5% CO2 atmosphere. After washing, monocytes
were surface stained by anti-human CD14 TriColor mAb
(Medac, Germany). Red blood cells were lysed using
FACS™ Lysing Solution (Becton Dickinson, Germany).
Cells were fixed and permeabilized by addition of 250 µl
Cytofix/Cytoperm™ (Becton Dickinson, Germany).
Finally, the retained intracellular TNF-α was stained by
the anti-TNF-α PE mAb. For a positive control, cells were
stimulated with 0.25 µg Lipopolysaccharide (LPS), fol-
lowing the same procedure as mentioned above.
Surface activation markers
Surface activation markers were analyzed before (t = 0)
and after 2 h, 6 h, 24 h, 48 h, 72 h, and 96 h. For the detec-
tion of activation markers, anti-human CD69 PE (Holzel
Diagnostika, Germany), CD25 Fluoresceinisothiocyanat
(FITC), CD71 FITC, CD11b PE (Diaclone Research, Ger-
many) and HLA-DR PerCP (Becton Dickinson, Germany)
mAbs were used. For a positive control, cells were stimu-
lated with 10 ng/ml Phorbol-12-Myristat-13-Acetat
(PMA) and 1 µg/ml Ionomycin for 2 h, while macro-
phages/monocytes were stimulated with 1.25 µg/ml LPS
for 2 h. To distinguish between leukocytes, additional sur-
face markers, anti-human CD45 Allophycocyanine
(APC), CD19 APC (Caltag Laboratories, Germany), CD3
Tri/Color (DAKO, Germany) and CD14 FITC (Diaclone
Research, Germany) mAbs were used for detection. Blood
samples (40 µl) were stained for 4-color flow cytometry
analysis. After staining, red blood cells were lysed, subse-
quently leukocytes were analyzed. Antibody specificity
was validated by isotype controls (Becton Dickinson,
Germany).
Specific antibody development
Serum samples were analyzed before (t = 0) and after 24
h, 48 h, 72 h, 96 h, 10 d, 12 d, and 14 d. Specific anti-
LK565 antibodies were determined via indirect ELISA.
Indirect ELISA was performed in a 96-well plate by LK565
immobilization overnight. Optimal concentrations had
previously been determined by common cross-testing.
Serum was obtained from blood samples after centrifuga-
tion at 400 G. After incubation for 2 h at room
temperature, detector antibodies (Biozol Diagnostica
GmbH, Germany) were added and incubated at 4°C over-
night. Washing was carried out with phosphate buffered
saline (PBS) and blocking buffer. For detection, alkaline
phosphatase (AP)-linked goat-anti-human IgG and IgM
Apical 4 chamber view with LK565 Figure 2
Apical 4 chamber view with LK565 Apical 4 chamber view before (a) and 1 minute after (b) intravenous LK565 application 
(4 mg/kg BW). Device: SONOS 5500, S3 Probe, harmonicCardiovascular Ultrasound 2004, 2:16 http://www.cardiovascularultrasound.com/content/2/1/16
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antibodies with para-Nitrophenylphosphate (p-NPP) as
substrate (Biozol Diagnostica GmbH, Germany) were
used. After development, the enzyme reaction was
stopped with 0.5 M NaOH and measured at λ = 405 nm.
For the functional (positive) control of the indirect ELISA,
total immunoglobuline was captured polyclonally. For a
negative control, the serum of a person who had not been
exposed to the contrast agent was obtained.
Results
We investigated 15 volunteers in a clinical phase one trial
over a period of 14 days. The kinetics of activation surface
markers CD69, CD25, CD71 and CD11b on leukocytes,
the phagocytosis capacity, and TNF-α production in
monocytes were analyzed, as was the specific antibody
production after LK565 application.
The expression of CD69 [15], CD25 [16], CD71, HLA-DR
[17], and CD11b [18] is increased after activation [19].
CD69 will be presented quickly after activation on almost
all leukocytes normally after some hours but on neu-
trophils even after a few minutes due to mobilisation of
intracellular storages [20]. The α-chain of the IL-2 receptor
CD25, also known as the high-affinity receptor on lym-
phocytes, is developed after 6 hours at the earliest and up
to 1–2 days. Transferrin receptor CD71 correlates directly
with cell proliferation and a late marker which can be
expected after 3–4 days similar to antigen presentation via
MHC-II analyzed as HLA-DR. Integrin expression
(CD11b) on monocytes and neutrophils is associated
with phagocyte migration into tissue [21].
Independent of dosage or repeated contact, the contrast
agent LK565 was well tolerated by all volunteers. After
exposure to LK565 no erythema, no drop in blood pres-
sure, neither significant change of the heart frequency nor
fever occurred (data not shown). The volunteers did not
complain of relevant clinical symptoms such as chest dis-
comfort or asthenia. It exhibited good opacification of
both ventricles a few seconds after application (figure 2).
While the minimum dosage of 0.15 mg/kg LK565 was suf-
ficient for just one echocardiogram, a suitable duration of
echo contrast was obtained at a 0.4 mg/kg dose. A further
increase in dosage provided no improvement in quality or
contrast duration (data not shown).
The uptake of LK565 led to the saturation of phagocytes.
The uptake capacity of the phagocytes from blood sam-
ples 6 h after injection was exhausted (figure 4). Neither
macrophages nor neutrophils phagocytosed any more
labeled bacteria after LK565 uptake, the observed effect
was reversible. After 24 h the phagocytic capacity reached
almost the starting level.
Apical 4 chamber view with LK565 Figure 3
Apical 4 chamber view with LK565 Apical 4 chamber 
view before (a), 1 minute (b), and 30 minutes (c) after intra-
venous LK565 application (4 mg/kg BW) and intermittent 
ultrasound exposure. Device: SONOS 5500, S3 Probe, 
harmonicCardiovascular Ultrasound 2004, 2:16 http://www.cardiovascularultrasound.com/content/2/1/16
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During the first 24 h an increase in intracellular TNF-α
production was detected in monocytes and macrophages
(figure 5a). However, in relation to the positive control
after 2 h of LPS stimulation, the slight increase in
intracellular TNF-α was negligible. No connection
between repeated exposure and dosage was found. The
amount of intracellular TNF-α decreased to starting levels
after 24 h.
An increase in integrin expression CD11b was detected on
monocytes and macrophages 6 hours after application.
Compared to the positive control, the upregulation of the
integrin was only poor. In all cases, the upregulation of
the integrin was only of brief duration and returned to
normal levels after 24 h (figure 6d). Only a slight and
short increase in CD69 after 6 h was determined in neu-
trophils in a few cases. Most volunteers exhibited no
CD69 increase in neutrophils. Even less CD69 expression
was found on monocytes and macrophages where CD69
Phagocytosis capacity after LK565 exposure Figure 4
Phagocytosis capacity after LK565 exposure Phagocytosis capacity refer to opsonized E. coli of neutrophils (a) and 
monocytes (b) in vitro illustrated in percent of control after LK565 exposure (n = 15, error bars show standard error).
TNF-α and specific antibody production after LK565 application Figure 5
TNF-α and specific antibody production after LK565 application (a) intracellular TNF-α (Monocytes) after LK565 
exposure relative to starting value and (b) LK565 specific antibody production (IgM, IgG) relative to positive control (n = 15, 
error bars show standard error).Cardiovascular Ultrasound 2004, 2:16 http://www.cardiovascularultrasound.com/content/2/1/16
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stimulation is associated with the production of prostag-
landines, leukotriens and TNF-α. Only minor CD69
expression was observed on T-cells and on B-cells (figure
6c). No increase of CD25 and CD71 (also on monocytes)
was detected (figure 6a,6b).
Discrete MHC class II (HLA-DR) upregulation on macro-
phages and lymphocytes was observed (figure 7a). We
found no further evidence of an adaptive immune
response via antibody production. None of the serum
samples during our clinical trial exhibited any
development of specific antibodies (IgM, IgG) versus the
contrast agent (figure 5b).
Discussion
The results show that there is only a slight activation of
leukocytes esp. of phagocytes after application of LK565,
a particular contrast agent based on a polymer of the nat-
urally occurring amino aspartic acid. No specific antibody
development against the contrast agent was detected.
Thus, the risk of a major immunological activation cas-
cade after repeated dosage can be regarded as minor. Since
LK565 does not lead to an adaptive immune activation in
this study, the possibility of an overexpression of IgE,
which plays a key role in allergic diseases, also becomes
more unlikely. Although none of the 15 volunteers
enrolled in this phase I study developed an allergic-type
reaction, such reactions could, however, occur in further
phases of clinical testing or application. An allergic reac-
Activation marker expression after LK565 application Figure 6
Activation marker expression after LK565 application CD25, CD71, CD69 and CD11b expression on different cell 
types after LK565 exposure relative to starting value (n = 15, error bars show standard error).Cardiovascular Ultrasound 2004, 2:16 http://www.cardiovascularultrasound.com/content/2/1/16
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tion against a pharmaceutical drug is a rare event which is
impossible to exclude even in large clinical studies.
An increase in CD11b/CD18 is connected with phagocy-
tosis and the diapedesis readiness of phagocytes. LK565 is
eliminated from the blood stream via phagocytosis, there-
fore neutrophils exhibited an increase in CD11b expres-
sion and phagocytosis activity. This is also connected to a
temporary higher intracellular TNF-α level in monocytes.
On lymphocytes, especially T-cells, the cascade of CD69,
CD25 and CD71 is closely related to an immune
response. After expression of CD69, the interlinkage of the
receptor leads to proliferation and secretion of IL-2, IFN-γ
and TNF-α. After effective activation, the T-cells secrete IL-
2 which activates the development of the high-affinity IL-
2 receptor CD25 and therefore launches cell proliferation
with an expression of CD71 after 3 – 4 days. During our
study after LK565 application no major activation cascade
was detected on either T-cells or B-cells.
As mentioned above, the best contrast performance for
echocardiography was obtained at a LK565 dosage of 0.4
mg/kg. Opacification of both ventricles was not enhanced
by a further increase in dosage. Bearing in mind the fact
that the contrast agent is phagocytosed and uptake capac-
ity is limited, it is recommended that the daily dosage
does not exceed 90 mg, which is equivalent up to three
echocardiograms per day.
Conclusions
To minimize the risk of an undesirable adverse event such
as an anaphylactoid reaction, immunological studies
should be included in clinical trials for new UCAs. The use
of LK565 as another new ultrasound contrast agent (UCA)
with a comfortable duration of signal enhancement esp.
in echocardiography should be encouraged as a means to
provide additional diagnostic information without caus-
ing a major activation cascade or triggering an adaptive
immune response. This can be an advantage for the "diffi-
cult-to-image" patient with adverse reactions related to
other UCAs.
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